Tim Knight shares about his professor and colleague, Kenneth Sandifer, professor emeritus of biology at Ouachita.

“For many cell-based therapies, progress comes from connecting the right pieces at the right moment,” Klein said. “When ...

How do you translate ancient Palmyrene script from a Roman tombstone? How many paired tendons are supported by a specific ...

Adam Feuerstein, a senior writer and biotech columnist, is the author of Adam’s Biotech Scorecard, a subscriber-only newsletter about the crossroads of drug development, business, Wall Street, and ...

The performance metrics speak volumes. The iShares Biotechnology ETF (NASDAQ: IBB) has climbed 29.51% year to date through December 29, while the State Street SPDR S&P Biotech ETF (NASDAQ: XBI) has ...

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...

After layoffs this fall, Mythic Therapeutics is winding down, putting all its assets up for sale and terminating its only clinical trial. “The company is in the process of winding down and selling ...

The US Congress is poised to enact bipartisan legislation that would block some Chinese biotechnology companies from government-funded contracts and authorize the Trump administration to bar US ...

Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.